Anirban Maitra · @Aiims1742“Amazing news today, culmination of years of research & clinical trials in #PancreaticCancer. The @RevMedicines approval for Rasonque (Daraxonrasib) will open many doors, including other inhibitors in this space & combinations. @OncoAlert @KRASKickers”
View post ↗See the full RASolute 302 KOL reaction on KOL Pulse →Discussion highlighted the importance of CNS activity in early-stage ALK-positive lung cancer, with commentary noting that alectinib has succeeded where crizotinib, which lacks CNS activity, has failed. Separately, the FDA approval of daraxonrasib (RASONQUE) for metastatic pancreatic adenocarcinoma — with no RAS-mutation documentation required on the label — is being seen as a milestone for the broader RAS-directed oncology field, with KOLs expressing hope for the development of such drugs for lung cancer patients.
“CNS activity is key in early stage ALK lung cancer, crizotinib doesn’t have it & fails where alectinib succeeded”
— @FordePatrick · ALK+ NSCLC CNS Activity · View post ↗📌 Amplified by @KolPulseAI
“Can’t wait for the development of this and other KRAS-On drugs for #lungcancer. We have patients desperately waiting for better treatment options.”
— @Latinamd · KRAS Inhibitors in Lung Cancer · View post ↗📌 Amplified by @KolPulseAI
The prospective, randomized SENOMAC-ULTRA non-inferiority trial is evaluating the omission of axillary lymph node dissection (ALND) in patients with ultrasound-detectable axillary metastases in primary breast cancer treated with upfront surgery. Separately, discussion noted positive phase 3 results for a topoisomerase inhibitor ADC in both metastatic triple-negative and HR+/HER2- breast cancer, prompting questions about its clinical integration.
“Omission of ALND axillary lymph in Ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial”
— @raquel_ciervide · SENOMAC-ULTRA trial · View post ↗
“How will we integrate yet another topoisomerase inhibitor ADC in MBC?”
— @drsarahsam · Topoisomerase inhibitor ADC integration · View post ↗📌 Amplified by @KolPulseAI
“Now with positive phase 3 results both in mTNBC and HR+/HER2- MBC 🎯”
— @PTarantinoMD · Topoisomerase inhibitor ADC · View post ↗📌 Amplified by @KolPulseAI
The U.S. FDA approved daraxonrasib (Rasonque), a multi-selective oral RAS inhibitor, for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or for patients who are not candidates for multiagent systemic therapy. The FDA label does not require documentation of KRAS status. In RASolute 302, median overall survival was 13.2 vs 6.7 months (overall population). Debate now centers on access: Revolution Medicines set the list price at $39,800 per 30-day supply, about $478,000 a year.
“FDA approved daraxonrasib…. One of oncology’s oldest walls just cracked…”
— @DrYukselUrun · Daraxonrasib approval · View post ↗📌 Amplified by @KolPulseAI
“The @FDA Daraxonrasib (Rasonque) approval is REALLY broad & the "OR" in the indication below potentially opens the door for a "soft 1st line" extension. Also, no requirement to document KRAS status, acknowledging that 95% of #PancreaticCancer harbor a mutation.”
— @Aiims1742 · Daraxonrasib label specifics · View post ↗📌 Amplified by @KolPulseAI
“It's priced at $500,000 a year.”
— @AlexBerenson · Daraxonrasib cost · View post ↗📌 Amplified by @KolPulseAI
Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Five-year results from the phase III KEYNOTE-564 study of adjuvant pembrolizumab for clear cell renal cell carcinoma (ccRCC) are now published in Annals of Oncology. A new phase 3 trial has also been initiated evaluating a DXd antibody-drug conjugate (ADC) combination for the adjuvant treatment of high-risk muscle-invasive urothelial cancer. Other new research includes a pooled analysis of two phase 2 trials on metastasis-directed therapy with or without pembrolizumab for oligometastatic ccRCC.
“Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study”
— @Annals_Oncology · KEYNOTE-564 5-Year Data · View post ↗
“has initiated a phase 3 trial evaluating one of our DXd ADCs as part of a combination regimen for the adjuvant treatment of patients w/ high-risk muscle invasive urothelial cancer”
— @DaiichiSankyoUS · New Adjuvant MIBC Trial · View post ↗📌 Amplified by @KolPulseAI
“Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials”
— @EUplatinum · Oligometastatic ccRCC · View post ↗
“Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma”
— @labratprats · Translocation RCC Research · View post ↗A proposed CMS memo to limit Medicare transplant coverage to ISS stage 2 or 3 myeloma, excluding ISS stage 1, is drawing significant opposition. Separately, a randomized controlled trial of Venetoclax/Dexamethasone versus Pomalidomide/Dexamethasone in t(11;14) relapsed/refractory multiple myeloma (RRMM) is being highlighted. A new study also suggests that with T-cell engager (TCE) therapy in RRMM, early lymphocyte recovery kinetics are more informative for predicting response and outcomes than baseline absolute lymphocyte count.
“If you haven't already, please comment on proposed CMS memo that limits Medicare transplants to ISS 2 or 3 (i.e.: not guaranteed for ISS 1 myeloma).”
— @RahulBanerjeeMD · CMS transplant policy · View post ↗
“Our takeaway: with TCE in RRMM, ALC kinetics may be more informative than baseline ALC. Early lymphocyte recovery tracked with response & outcomes.”
— @MansiShahMD · T-cell engager biomarkers · View post ↗
“Highlighting results of a RCT Venetocloax/Dex vs Pom/Dex in t(11;14) RRMM!!”
— @Abdallah81MD · Venetoclax in t(11;14) RRMM · View post ↗A new publication identifies immunosenescence as a key driver of CAR T-cell product failure in some patients with CLL. The study found that senescence-associated features were detectable before infusion, worsened during manufacturing, and correlated with poor in vivo expansion and survival. The authors also noted that ibrutinib attenuated these senescence features, suggesting starting T-cell fitness is a potentially modifiable factor.
“Why do some CLL-derived CAR T-cell products fail even when they still produce inflammatory cytokines? @jh_noll et al (link in reply) identifies immunosenescence, not exhaustion alone.”
— @BLLPHD · CLL CAR-T Failure · View post ↗
“We’ve started checking IgG and CMV for BsAbs in DLBCL. No preemptive IVIG like MM does but low threshold to initiate if insurance approves.”
— @dgermain21 · Bispecific Antibody Management · View post ↗“Ibrutinib attenuated senescence-associated features and SASP output and improved proliferative fitness. The broader message: starting T-cell fitness is measurable and potentially modifiable.”
— @BLLPHD · Modifying T-cell Fitness · View post ↗